칸델 테라퓨틱스 (CADL) 주가

칸델 테라퓨틱스(CADL)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $10.85 (-4.32%), 시가총액 $572.24M.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors.

핵심 지표

• 현재가: $10.85 (-4.32%)
• 시가총액: $572.24M
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NAS

칸델 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.

칸델 테라퓨틱스 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 적극 매수 (5.0 / 5)

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 4.09
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문